$CRVO News

CervoMed Shows Progress in Treating Rare Aphasia Condition

CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026

CervoMed Announces Data From Its Phase 2a Clinical Study Of Nonfluent Variant Primary Progressive Aphasia Shows Reduction In Mean Plasma Levels Of Neurofilament Light Chain

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

CervoMed To Present Neflamapimod, Oral, Small Molecule, Drug Candidate Targeting Critical Disease Processes Underlying Degenerative Disorders Of Brain, At ISFTD Annual Meeting

CervoMed to Participate in September Investor Conferences

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18

CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

CervoMed Presents New Insights Into Neflamapimod's Treatment Effects In Dementia with Lewy Bodies At The Alzheimer's Association International Conference 2026

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target